Trajenta 5 mg. FC tablets
PDF Leaflet Revision Date: 18 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
For improving glycaemic control in adults with type 2 diabetes mellitus.
Dosage (summary)
5 mg once daily, with or without food.
Onset of Action / Duration
Onset: 1.5 hours, Duration: >100 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Ritonavir
- Rifampicin
- Sulphonylureas
Contraindications
- Hypersensitivity to linagliptin
- History of pancreatitis
Common side effects
- Hypoglycaemia
- Nasopharyngitis
- Cough
Counselling Points
- Take at the same time each day
- Monitor blood glucose levels
- Report signs of pancreatitis
Serious warnings
- Risk of pancreatitis
- Bullous pemphigoid
- Rhabdomyolysis
Important Disclaimer
The Trajenta 5 mg. FC tablets professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
